What You Should Know:
- PsychoGenics Inc., a provider of AI-enabled phenotypic drug discovery and preclinical CRO services launches eCube®, a novel pharmaco-electroencephalography (“pharmacoEEG”) platform.
The platform supports phenotypic drug discovery, which unlike traditional target-based drug discovery, can identify novel treatments with multiple targets.
How eCube Works
eCube measures drug-induced changes to EEG spectra data and utilizes machine learning classifiers trained
Read More
neuropsychiatric disorders
Mindstrong Health, Takeda Partner to Develop Digital Biomarkers for Mental Health Conditions
Mindstrong Health, a digital health startup transforming the diagnosis and treatment of neuropsychiatric disorders, has entered into a partnership with Takeda Pharmaceutical Company Limited to explore the development of digital biomarkers for selected mental health conditions, in particular schizophrenia and treatment-resistant depression.In this decade, neuropsychiatric disorders represent the largest source of medical disability for people under age 50. The costs are among the highest of all
Read More
